You are here

  • Home
  • Archive
  • Volume 74, Issue Suppl 2
  • AB0800 Comparison of One Year Response to Treatment-to-Target Strategy by Methotrexate Subcutaneous Monotherapy and Its Combination with Adalimumab in Active Early Peripheral Psoriatic Arthritis (Results of an Ongoing Open-Label Remarca Study)

Article info

Article menu
Download PDFPDF
Abstracts Accepted for Publication
Psoriatic arthritis
AB0800 Comparison of One Year Response to Treatment-to-Target Strategy by Methotrexate Subcutaneous Monotherapy and Its Combination with Adalimumab in Active Early Peripheral Psoriatic Arthritis (Results of an Ongoing Open-Label Remarca Study)

Authors

Citation

Loginova E, Korotaeva T, Glazkov A, et al
AB0800 Comparison of One Year Response to Treatment-to-Target Strategy by Methotrexate Subcutaneous Monotherapy and Its Combination with Adalimumab in Active Early Peripheral Psoriatic Arthritis (Results of an Ongoing Open-Label Remarca Study)
Annals of the Rheumatic Diseases 2015;74:1167.

Publication history

  • First published June 9, 2015.
Online issue publication 
April 13, 2016

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© 2015, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions